FOXO4-DRI Peptide Reverses Age-Related Male Infertility by Clearing Senescent Cells

Male aging is frequently associated with a decline in fertility, a complex issue impacting quality of life. A key contributor to this decline is the accumulation of senescent cells—cells that have stopped dividing but remain metabolically active, often secreting harmful factors. Specifically, Leydig cells in the testes, which are crucial for supporting spermatogenesis (sperm production), become senescent with age, creating a detrimental microenvironment. The transcription factor FOXO4 is known to be highly expressed in these senescent cells, where it binds to p53 (a tumor suppressor protein), preventing the senescent cells from undergoing programmed cell death (apoptosis) and allowing them to persist. This study addresses the critical knowledge gap of how to specifically target and eliminate senescent Leydig cells to restore healthy spermatogenesis in aged males.

The study found that in vitro, FOXO4-DRI effectively induced apoptosis (programmed cell death) in senescent Leydig cells, indicating its ability to clear these harmful cells. This clearance led to a significant reduction in the secretion of certain Senescence-Associated Secretory Phenotype (SASP) factors—a collection of molecules secreted by senescent cells that can damage surrounding tissues. Furthermore, the improved microenvironment resulting from reduced SASP secretion enhanced the proliferation of cocultured GC-1 SPG cells, suggesting a direct benefit to early sperm development. The most impactful finding came from the in vivo experiments: > FOXO4-DRI treatment in naturally aged mice resulted in increased sperm quality and improved spermatogenesis, directly counteracting age-related fertility decline. This demonstrates a clear therapeutic effect, showing that targeting senescent Leydig cells can restore reproductive function.